# Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

> **NCT04238637** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 50 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT04238637
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-11-01
- **Primary completion:** 2026-08
- **Final completion:** 2027-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04238637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04238637, "Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04238637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*